Found 27 articles
MDimune Inc. announced today that it took up residence at Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’), located in Shanghai, China, starting in September.
MDimune Inc., a Korean biotech company developing BioDrone™ platform technology, has won the Bronze Award at the 2023 Edison Awards.
BioDroneTM next-generation drug delivery platform honored for excellence alongside other innovators and innovations in the Health, Medical & Biotech category
MDimune announces a collaboration with Hanyang University on the projects selected through the 3rd BioDrone™ Award
MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), announces funding of two research projects focusing on next-generation drug delivery and novel therapeutics.
MDimune announced the development of the GMP manufacturing process for cell-derived vesicles in the latest publication
MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), announced the publication of data in the Journal of Extracellular Biology showing the development of the Good Manufacturing Practice (GMP)-compliant manufacturing process of CDVs and their biological activities.
MDimune Inc. enters into a Research Collaboration Agreement with Australian National University to collaborate on the development of therapeutics for age-related macular degeneration
October xxth, 2022 – MDimune Inc., a Korean biotech company developing BioDroneTM platform technology based on cell-derived vesicles (CDVs), announced a research collaboration agreement with the Clear Vision Research Lab (CVR Lab) at the Australian National University (ANU), experts in retinal degenerations.
MDimune acquires intellectual property and partners with Ewha Womans University Medical Center to develop inflammatory bowel diseases therapeutics
MDimune, Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), announced a business agreement with Ewha Womans University Medical Center (EUMC) and acquisition of IP from EUMC to develop therapeutics for inflammatory bowel diseases (IBD). MDimune and EUMC agreed to extend their research collaboration which will play a pivotal role in innovative IBD drug development.
MDimune, Inc., a Korean biotech company developing BioDroneTM platform technology based on cell-derived vesicles (CDVs), enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss.
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.
MDimune has announced the joint research agreement with YiPSCELL to develop BioDrone® Platform therapeutics based on induced pluripotent stem cells (iPSCs).
It's been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
MDimune Inc., a biotech company developing BioDrone® platform technology based on cell-derived vesicles (CDVs), has announced the finalists of the research-funded project; the 2021 BioDrone® Award.
MDimune Inc. and Kainos Medicine, Inc., has inked a collaboration pact and possible licensing deal with MDimune Inc. for disruptive cancer therapy development based on cell-derived vesicles (CDVs) like extracellular vesicles (EVs) loaded with Fas-associated Factor 1 (FAF1) expressing mRNA or protein.
NeoCura Bio-Medical Technology Co., Ltd, a leading AI-enabled RNA precision medicine company based on research, development and MDimune Inc., a leading extracellular vesicle (EV)-based drug delivery platform company, has announced the signing of collaboration focused on mRNA delivery for oncological therapeutics.
Successful demonstration of BioDrone® platform-based drug delivery and confirmed restoration of the myogenic potential of Prokr1-deficient C2C12 myoblasts
MDimune Inc., a leading cell-derived vesicles (CDVs) company in South Korea has announced the outcomes of the research collaboration with Prof. Joonghoon Park’s team at Seoul National University.
Mdimune Inc. Announces Research Collaboration with the Seoul National University for Gene Editing based on Cell-derived Vesicles (CDVs)
The outcomes of this research may revolutionize a breakthrough of the current limitations in gene editing nuclease delivery techniques.
Vect-Horus and MDimune Collaborate to Develop a Novel Approach to CNS Drug Delivery Based on Vectorized Cell-derived Vesicles (CDVs)
MDimune Inc. and Vect-Horus are please to announce today the signing of a Research Collaboration Agreement.
Biopharma and life sciences from across the globe provide updates on their businesses and pipelines.
Reyon Pharmaceuticals Co. Ltd. (“Reyon”), a bio & chemical pharmaceutical company based on research, production, and sales capabilities and MDimune Inc. (“MDimune”), a leading extracellular vesicle (EV)-based drug delivery platform company, has announced the signing of a partnership focused on mRNA delivery for antivirus vaccine and rare genetic disorder.
Navigo Proteins and MDimune Enter into a Research Collaboration on Affilin®-Mediated Targeting of Extracellular Vesicles
Solid tumor-specific scaffold protein ligands from Navigo combined with MDimune’s BioDrone® technology to create novel targeted extracellular vesicle-based therapeutics